FL-ELEVATE-PRIZE
The Elevate Prize Foundation, in collaboration with MIT Solve, announced today the winners of the second annual Elevate Prize, which distributes $5 million across 10 diverse social entrepreneurs working to solve pressing issues around the world. This year’s winners, selected from a pool of over 1,200 applicants, stand out for their innovative approaches to global causes, such as LGBTQIA+ rights, access to health care, social justice reform and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005942/en/
Founded in 2019 by Joseph Deitch, The Elevate Prize Foundation aims to “Make Good Famous” by partnering with rising activists and social entrepreneurs and providing them with resources to raise visibility of their work, multiplying their ability to mobilize support – whether online or on-the-ground. The 2021 winners of the Elevate Prize will each receive a minimum of $300,000 in prize funding, as well as leadership development services, social media training, mentorship, and other support needed to reach a wider audience and grow their following.
“This year’s Elevate Prize winners are an exceptional group of creative problem-solvers who have managed to catalyze change through such challenging times,” said Joseph Deitch, Founder, Elevate Prize Foundation. “In a world that is increasingly looking for leaders to lead … and to inspire us, we are so fortunate to have these incredible individuals and organizations show us the way. We look forward to partnering and co-creating with them to expand their impact, and to share their stories with the world.”
The winners of the 2021 Elevate Prize are:
- Amanda Alexander, Detroit Justice Center , which works alongside communities to transform the justice system and promote equitable and fair cities.
- Krista Donaldson, Equalize Health , which provides access to medical care and addresses the leading causes of maternal and newborn mortality through innovative tech.
- Aparna Hegde, ARMMAN , which uses mobile technology to enable healthy pregnancies, safe deliveries, and healthy childhoods.
- Kaushik Kappangantulu, Kheyti , which designs, adapts and implements low-cost farming solutions to help farmers increase yield and predictability of produce, offering a “greenhouse-in-a-box” – an affordable, modular greenhouse bundled with full-stack services.
- Nisha Ligon, Ubongo , the leading children’s entertainment producer in Africa, which harnesses the power of entertainment to reduce inequalities in education across Africa.
- Heejae Lim, TalkingPoints , which connects and empowers families in under-resourced, multilingual communities, using communications technology to bridge crucial gaps between students, families, teachers, and schools.
- Uzoma Orchingwa , Ameelio , which works to reduce the prison population, decrease recidivism and ensure incarcerated individuals can stay in touch with the outside through free-to-use communication apps.
- Alexander Roque, Ali Forney Center , a space dedicated to empowering homeless LGBTQIA+ youth to live independently and get back on their feet.
- Rebecca van Bergen, Nest , which supports the responsible growth and creative engagement of the artisan and maker economy to build a world of greater gender equity and economic inclusion.
- Tony Weaver , Weird Enough Productions , which runs a national education program that combines diverse comic books with an anti-racist and equity-based learning curricula.
“We’re thrilled to highlight such a radically diverse group of winners this year, all working on a wide-range of important issues around the world,” said Carolina García Jayaram, CEO of The Elevate Prize Foundation. “We look forward to helping grow their audience and impact, ultimately making philanthropy and social change more accessible to all.”
The Elevate Prize 2021 winners were selected by a renowned judging panel, composed of purpose-driven leaders in business, academia, media and beyond, including Diane von Furstenberg, fashion designer and philanthropist; Maria Elena Salinas, journalist and CBS news contributor; Stephanie Mehta, Editor-in-Chief of Fast Company; and Natalie Tran, Executive Director of the CAA Foundation.
About The Elevate Prize Foundation
Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, The Elevate Prize Foundation aims to serve as an engine for social good by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize, which is awarded to 10 or more global leaders tackling pressing issues in innovative ways. The Elevate Prize Catalyst Award, another one of the Foundation’s programs, recognizes prominent individuals for their commitment to inspiring global social action and using their influence for the good of humanity. Through the Elevate Giving program, the Foundation allows everyday people the opportunity to engage in philanthropy. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook , Instagram , LinkedIn , and Twitter .
About MIT Solve
Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
